Edition:
United States

Mallinckrodt Plc (MNK.N)

MNK.N on New York Stock Exchange

21.81USD
15 Feb 2019
Change (% chg)

$0.03 (+0.14%)
Prev Close
$21.78
Open
$21.97
Day's High
$22.01
Day's Low
$21.55
Volume
280,076
Avg. Vol
454,126
52-wk High
$36.63
52-wk Low
$11.66

Chart for

About

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and... (more)

Overall

Beta: 2.27
Market Cap(Mil.): $1,817.06
Shares Outstanding(Mil.): 83.31
Dividend: --
Yield (%): --

Financials

  MNK.N Industry Sector
P/E (TTM): 1.70 32.52 35.99
EPS (TTM): 12.84 -- --
ROI: 8.59 13.14 12.72
ROE: 20.18 14.13 13.73

FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

The U.S. Food and Drug Administration has declined to approve an abuse-deterrent version of Mallinckrodt Plc's opioid painkiller Roxicodone, saying some parts of the company's application need further evaluation.

Dec 12 2018

UPDATE 1-FDA declines to approve Mallinckrodt's abuse-deterrent opioid painkiller

Dec 12 The U.S. Food and Drug Administration has declined to approve an abuse-deterrent version of Mallinckrodt Plc's opioid painkiller Roxicodone, saying some parts of the company's application need further evaluation.

Dec 12 2018

FDA declines to approve reformulated Mallinckrodt opioid

Dec 12 Mallinckrodt Plc said on Wednesday the U.S. Food and Drug Administration declined to approve an abuse-deterrent version of its opioid painkiller Roxicodone.

Dec 12 2018

Mallinckrodt to spin off generics business, but to keep options open

Mallinckrodt Plc plans to spin off its specialty generics business to shareholders by the second half of 2019, but said it was still open to a sale of the unit.

Dec 06 2018

UPDATE 3-Mallinckrodt to spin off generics business, but to keep options open

* Branded drug co will rely on Acthar for nearly 50 pct of sales

Dec 06 2018

Mallinckrodt plans to spin off specialty generics business

Dec 6 Drugmaker Mallinckrodt Plc said on Thursday it planned to spin off its specialty generics business to shareholders by the second half of 2019.

Dec 06 2018

UPDATE 2-Trump administration proposes production quota cuts for six opioids

WASHINGTON/NEW YORK, Aug 16 The Trump administration on Thursday proposed that U.S. drugmakers cut production quotas of the six most abused opioids by 10 percent next year to fight a nationwide addiction crisis.

Aug 16 2018

Earnings vs. Estimates